ESR1 and breast carcinoma: In view of the potential value of new diagnostic tools such as the recently reported Y1R selective 99mTc-labeled peptide [11], we performed preclinical investigations on the expression of Y1Rs and ERs in breast cancer cells and tumors using well-established ER and NPY receptor agonists and antagonists.